By controlling for ovarian suppression, OPTIMA shows Prosigna works equally well in pre and postmenopausal high-risk early breast cancer.
Iain MacPherson, PhD
Advertisement
Articles by Iain MacPherson, PhD
OPTIMA trial data show genomic testing helps many patients with high‑risk breast cancer skip chemotherapy safely and start endocrine therapy sooner.
ASCO 2026 clinicians highlighted unmet needs from navigating complex treatment decisions and overcoming translation gaps, to optimizing regimens.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
2
Nephrologists Weigh Wins, Losses From 5 Years of Value-Based Kidney Care
3
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
4
FSGS Treatment and Low IgAN Drug Uptake: Jai Radhakrishnan, MD, MS
5